Table 2.
Prevalence of metabolic syndrome and metabolic syndrome components in 26,609 young adults.
Author | Country | Total (n) | MetSyn | WC | HDL | TG | BP | FBG | |
---|---|---|---|---|---|---|---|---|---|
Harmonized | Al Dhaheri et al. (2016) | UAE | 555 | 38 (6.8) | 101 (18.2) | 271 (48.8) | 8 (1.4) | 30 (5.4) | 54 (9.7) |
Bennett et al. (2014) | Jamaica | 746 | 6 (0.8) | 108 (14.5) | 343 (46.0) | 4 (0.5) | 154 (20.6) | 8 (1.1) | |
Ferguson et al. (2010) | Jamaica | 839 | 10 (1.2) | 134 (16.0) | 393 (46.8) | 5 (0.6) | 56 (6.7) | 10 (1.2) | |
Gavrila et al. (2011)a | Spain | 292 | 18 (6.2) | 81 (27.7) | 49 (16.8) | 24 (8.2) | 48 (16.4) | 11 (3.8) | |
Gupta et al. (2009) | India | 486 | 12(2.5) | 51 (10.5) | 150 (30.9) | 27 (5.6) | 15 (3.1) | 31 (6.4) | |
Huang et al. (2015) | Taiwan | 355 | 24 (6.8) | 63 (17.7) | 46 (20.6) | 32 (9.0) | 123 (34.6) | 4 (1.1) | |
Kaduka et al. (2012) | Kenya | 90 | 9 (10.0) | 17 (18.9) | 47 (52.2) | 3 (3.3) | 51 (56.7) | 1 (1.1) | |
Lin et al. (2014) | China | 323 | 22 (6.8) | 180 (55.7) | 63 (19.5) | 40 (12.4) | 20 (6.2) | 22 (6.8) | |
Martins et al. (2015)a | Brazil | 2031 | 242 (9.0) | 646 (31.8) | 851 (41.9) | 254 (12.5) | 465 (22.9) | 73 (3.6) | |
Sy et al. (2014)a | Philippines | 861 | 108 (12.5) | 173 (20.1) | 467 (54.2) | 171 (19.9) | 127 (14.8) | 144 (16.7) | |
Overall | 6578 | 430 (6.5%) | 1554 (23.6%) | 2707 (41.2%) | 568 (8.6%) | 1089 (16.6%) | 358 (5.4%) | ||
NCEP –ATPIII | Erem et al. (2008) | Turkey | 1306 | 93 (7.1) | 182 (13.9) | 318 (21.3) | 183 (14.0) | 424 (32.5) | 25 (1.9) |
Gündogan et al. (2009)a | Turkey | 84 | 10 (11.9) | 25 (29.8) | 19 (22.6) | 24 (28.6) | 20 (23.8) | 11 (13.1) | |
Huang et al. (2004) | USA | 163 | 1 (0.6) | 3 (1.8) | 22 (13.5) | 4 (2.5) | 2 (1.2) | 3 (1.8) | |
Li et al. (2010)a | China | 2532 | 101 (4.0) | 79 (3.1) | 742 (29.3) | 241 (9.5) | 519 (20.5) | 58 (2.3) | |
Manjunath et al. (2014) | India | 473 | 41 (8.7) | 76 (16.1) | 184 (38.9) | 37 (7.8) | 123 (26.0) | 42 (8.9) | |
Mikkola et al. (2007)a | Finland | 1099 | 38 (3.5) | 51 (4.6) | 212 (19.3) | 31 (2.8) | 565 (51.4) | 25 (2.3) | |
Sidorenkov et al. (2010) | Russia | 862 | 23 (2.7) | 19 (2.2) | 266 (30.9) | 83 (9.6) | 149 (17.3) | 6 (0.7) | |
Sinha et al. (2013) | India | 85 | 8 (9.4) | 18 (21.2) | 53 (62.4) | 18 (21.2) | 5 (5.9) | 7 (8.2) | |
Soysal et al. (2005) | Turkey | 285 | 18 (6.3) | 14 (4.9) | 40 (14.0) | 115 (40.4) | 25 (8.8) | 13 (4.6) | |
Overall | 6889 | 333 (4.8%) | 467 (6.8%) | 1856 (26.9%) | 736 (10.7%) | 1832 (26.6%) | 190 (2.8%) | ||
IDF | Bener et al. (2009)a | Qatar | 203 | 16 (7.9) | 16 (7.9) | 43 (21.2) | 30 (14.8) | 34 (16.7) | 8 (3.9) |
da Costa et al. (2011) | Brazil | 711 | 28 (3.9) | 90 (12.7) | 313 (44.0) | 35 (4.9) | 71 (10.0) | 35 (1.4) | |
da Silveira et al. (2010)a | Brazil | 3599 | 240 (6.7) | 618 (17.2) | 694 (19.3) | 598 (16.6) | 883 (24.5) | 1322 (36.7) | |
Gavrila et al. (2011)a | Spain | 292 | 18 (6.2) | 81 (27.7) | 49 (16.8) | 24 (8.2) | 48 (16.4) | 11 (3.8) | |
Gündogan et al. (2009)a | Turkey | 84 | 16 (19.0) | 25 (29.8) | 19 (22.6) | 24 (28.6) | 20 (23.8) | 11 (13.1) | |
Hildrum et al. (2007)a | Norway | 1615 | 19 (1.2) | 414 (25.6) | 459 (28.4) | 221 (13.7) | 499 (30.9) | 179 (11.1) | |
Huang et al. (2007)a | USA | 300 | 2 (0.7) | 8 (2.7) | 73 (24.3) | 27 (9.0) | 11 (3.7) | 27 (9.0) | |
Kanitkar et al. (2015) | India | 250 | 55 (22.0) | 139 (55.6) | 93 (37.2) | 71 (29.2) | 21 (8.4) | 44 (17.6) | |
Li et al. (2010)a | China | 2532 | 147 (5.8) | 79 (3.1) | 742 (29.3) | 241 (9.5) | 519 (20.5) | 58 (2.3) | |
Martins et al. (2015)a | Brazil | 2031 | 242 (11.9) | 646 (31.8) | 851 (41.9) | 254 (12.5) | 465 (22.9) | 73 (3.6) | |
Mikkola et al. (2007)a | Finland | 1099 | 75 (6.8) | 134 (12.2) | 212 (19.3) | 31 (2.8) | 565 (51.4) | 221 (20.1) | |
Sy et al. (2014)a | Philippines | 861 | 108 (9.1) | 173 (20.1) | 467 (54.2) | 171 (19.9) | 127 (14.8) | 144 (16.7) | |
Tope et al. (2013)a | USA | 376 | 35 (9.3) | 43 (11.4) | 73 (19.4) | 21 (5.6) | 38 (10.1) | 42(11.2) | |
Overall | 13,953 | 971 (7.0%) | 2466 (17.7%) | 4088 (29.3%) | 1750 (12.5%) | 3301 (23.7%) | 2150 (15.4%) | ||
AHA/NHBLI | Bener et al. (2009)a | Qatar | 203 | 15 (7.4) | 16 (7.9) | 43 (21.2) | 30 (14.8) | 34 (16.7) | 8 (3.9) |
Cheserek et al. (2014) | China | 200 | 1 (0.5) | 4 (2.0) | 19 (9.5) | 13 (6.5) | 24 (12.0) | 6 (3.0) | |
da Silveira et al. (2010)a | Brazil | 3599 | 213 (5.9) | 269 (7.5) | 694 (19.3) | 598 (16.6) | 883 (24.5) | 610 (16.9) | |
Dalleck and Kjelland (2012) | USA | 207 | 14 (6.8) | 12 (5.8) | 98 (47.3) | 28 (13.5) | 34 (16.4) | 15 (7.2) | |
de Kroon et al. (2008) | Netherlands | 642 | 48 (7.5) | 78 (12.1) | 187 (29.1) | 50 (7.8) | 274 (42.7) | 75 (11.7) | |
Fernandes and Lofgren (2011) | USA | 189 | 7 (3.7) | 14 (7.4) | 38 (20.1) | 33 (17.5) | 4 (2.1) | 14 (7.4) | |
Gavrila et al. (2011)a | Spain | 292 | 10 (3.4) | 31 (10.6) | 49 (16.8) | 24 (8.2) | 48 (16.4) | 11 (3.8) | |
Hildrum et al. (2007)a | Norway | 1615 | 19 (1.2) | 414 (25.6) | 459 (28.4) | 221 (13.7) | 499 (30.9) | 179 (11.1) | |
Huang et al. (2007)a | USA | 300 | 4 (1.3) | 8 (2.7) | 73 (24.3) | 27 (9.0) | 11 (3.7) | 27 (9.0) | |
Morrell et al. (2013) | USA | 1610 | 81 (5.0) | 209 (130) | 467 (29.0) | 258 (16.0) | 403 (25.0) | 64 (4.0) | |
Morrell et al. (2012) | USA | 2103 | 103 (4.9) | 94 (4.5) | 538 (25.6) | 350 (16.6) | 681 (32.4) | 177 (8.4) | |
Shahbazian et al. (2013) | Iran | 203 | 13 (6.4) | 26 (12.8) | 85 (41.9) | 47 (23.2) | 1 (0.5) | 35 (17.2) | |
Sharifi et al. (2009) | Iran | 934 | 70 (7.5) | 31 (9.7) | 714 (76.4) | 246 (26.3) | 56 (6.0) | 74 (7.9) | |
Tope et al. (2013)a | USA | 376 | 45 (12.0) | 43 (11.4) | 73 (19.4) | 21 (5.6) | 38 (10.1) | 42 (11.2) | |
Overall | 12,473 | 643 (5.2%) | 1309 (10.5%) | 3537 (28.4%) | 1946 (15.6%) | 2990 (24.0%) | 1337 (10.7%) |
Data are expressed as n (%).
MetSyn – metabolic syndrome; WC – abdominal obesity; HDL - atherogenic dyslipidaemia (low HDL); TG - atherogenic dyslipidaemia (raised triglycerides); BP - raised blood pressure; FBG – raised fasting glucose.
Indicates study used more than one definition of MetSyn and is included multiple times.